Form 13-F position report

NAUTILUS BIOTECHNOLOGY INC

Reported by Madrona Venture Group LLC

Company profile Manager portfolio Source filing
NAUT CUSIP 63909J108 Manager CIK 0001887785
Latest reported change

Reported 6,020,770 shares, unchanged from the prior quarter.

Reported value -41.1%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 18.8% This manager · Q4 2024
Shares 6,020,770 Quarter-end amount reported
Reported value $10,115,000 Fair value at quarter end
Consecutive quarters held 15 Through Q4 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q4 2025 Unchanged 6,020,770 0 (0.0%) 53.24% $11,741,000 2026-02-13
Q3 2025 Unchanged 6,020,770 0 (0.0%) 36.76% $5,087,000 2025-10-31
Q2 2025 Unchanged 6,020,770 0 (0.0%) 34.58% $4,364,000 2025-08-11
Q1 2025 Unchanged 6,020,770 0 (0.0%) 18.2% $5,184,000 2025-05-07
Q4 2024 Unchanged 6,020,770 0 (0.0%) 18.8% $10,115,000 2025-02-14
Q3 2024 Unchanged 6,020,770 0 (0.0%) 23.0% $17,159,000 2024-11-04
Q2 2024 Unchanged 6,020,770 0 (0.0%) 15.03% $14,089,000 2024-07-25
Q1 2024 Unchanged 6,020,770 0 (0.0%) 15.07% $17,701,000 2024-05-08
Q4 2023 Unchanged 6,020,770 0 (0.0%) 4.22% $18,002,000 2024-01-30
Q3 2023 Unchanged 6,020,770 0 (0.0%) 6.52% $19,026,000 2023-11-08
Q2 2023 Unchanged 6,020,770 0 (0.0%) 8.48% $23,300,000 2023-08-03
Q1 2023 Unchanged 6,020,770 0 (0.0%) 6.76% $16,678,000 2023-05-05
Q4 2022 Unchanged 6,020,770 0 (0.0%) 5.22% $10,837,000 2023-02-08
Q3 2022 Unchanged 6,020,770 0 (0.0%) 5.87% $12,764,000 2022-11-04
Q2 2022 Unchanged 6,020,770 0 (0.0%) 7.52% $16,196,000 2022-08-03
Q1 2022 Unchanged 6,020,770 0 (0.0%) 7.74% $26,130,000 2022-05-09
Q4 2021 Unchanged 6,020,770 0 (0.0%) 5.89% $31,188,000 2022-02-11
Q3 2021 Unchanged 6,020,770 0 (0.0%) 4.08% $30,663,000 2021-10-22
Q2 2021 New 6,020,770 +6,020,770 (0.0%) 7.75% $47,848,000 2021-10-15
Institutional context

Who else reported the position

98 managers reported NAUTILUS BIOTECHNOLOGY INC for Q4 2024.

Manager Activity Shares Change % of reported 13F Reported value Tenure
AH Capital Management L L C Unchanged 17,653,917 0 3.98% $29,658,581 5 qtrs
PERCEPTIVE ADVISORS LLC Unchanged 12,594,211 0 0.58% $21,158,274 15 qtrs
Cercano Management LLC Unchanged 7,172,985 0 0.31% $12,050,615 9 qtrs
Madrona Venture Group LLC This report Unchanged 6,020,770 0 18.8% $10,115,000 15 qtrs
BlackRock Inc Reduced 3,068,737 -496,506 < 0.01% $5,155,478 2 qtrs
VANGUARD GROUP INC Added 2,778,449 +12,106 < 0.01% $4,667,794 14 qtrs
Comprehensive Financial Management LLC Reduced 2,207,619 -1 0.1% $3,708,800 15 qtrs
Bain Capital Life Sciences Investors LLC Reduced 1,759,000 -241,000 0.35% $2,955,120 15 qtrs
AMAZON COM INC Unchanged 1,457,055 0 0.09% $2,447,852 15 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 1,142,542 +7,000 < 0.01% $1,919,736 15 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2024
Filed
February 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
6,020,770
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.